Bernard Escudier

Bernard Escudier

UNVERIFIED PROFILE

Are you Bernard Escudier?   Register this Author

Register author
Bernard Escudier

Bernard Escudier

Publications by authors named "Bernard Escudier"

Are you Bernard Escudier?   Register this Author

100Publications

3783Reads

44Profile Views

Sequencing and Combination of Systemic Therapy in Metastatic Renal Cell Carcinoma.

Eur Urol Oncol 2019 Sep 1;2(5):505-514. Epub 2019 Aug 1.

Institut Gustave Roussy, Villejuif, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.euo.2019.06.022DOI Listing
September 2019

A new prognostic model for survival in second line for metastatic renal cell carcinoma: development and external validation.

Angiogenesis 2019 Aug 9;22(3):383-395. Epub 2019 Feb 9.

Departments of Medical Oncology, Gustave Roussy, 114 Rue Edward Vaillant, 94800, Villejuif, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10456-019-09664-2DOI Listing
August 2019

Combination Therapy as First-Line Treatment in Metastatic Renal-Cell Carcinoma.

Authors:
Bernard Escudier

N Engl J Med 2019 03 16;380(12):1176-1178. Epub 2019 Feb 16.

From the Gustave Roussy Cancer Campus, Villejuif, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMe1900887DOI Listing
March 2019

Sorafenib: key lessons from over 10 years of experience.

Expert Rev Anticancer Ther 2019 Feb 21;19(2):177-189. Epub 2018 Dec 21.

c Department of Gastroenterology and Hepatology , Kindai University Faculty of Medicine , Osaka , Japan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14737140.2019.1559058DOI Listing
February 2019

The role of tivozanib in advanced renal cell carcinoma therapy.

Expert Rev Anticancer Ther 2018 11 21;18(11):1113-1124. Epub 2018 Aug 21.

f Genitourinary Oncology Service, Department of Medicine , Memorial Sloan Kettering Cancer Center , New York , NY , USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14737140.2018.1508348DOI Listing
November 2018

Treating patients with renal cell carcinoma and bone metastases.

Expert Rev Anticancer Ther 2018 11 13;18(11):1135-1143. Epub 2018 Sep 13.

a Department of Medical Oncology , Gustave Roussy , Villejuif , France.

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/14737140.2018.1
Publisher Site
http://dx.doi.org/10.1080/14737140.2018.1520097DOI Listing
November 2018

Sunitinib Alone or after Nephrectomy in Renal Cancer.

N Engl J Med 2018 11;379(19):1878

Université Paris–Descartes, Paris, France

View Article

Download full-text PDF

Source
http://www.nejm.org/doi/10.1056/NEJMc1811532
Publisher Site
http://dx.doi.org/10.1056/NEJMc1811532DOI Listing
November 2018

Long-term efficacy of crizotinib in a metastatic papillary renal carcinoma with MET amplification: a case report and literature review.

BMC Cancer 2018 Nov 22;18(1):1159. Epub 2018 Nov 22.

Department of Medical Oncology, Institut Paoli-Calmettes, 232 Bd de Sainte-Marguerite, 13009, Marseille, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12885-018-5049-3DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6251103PMC
November 2018

Sexual Disorders of Patients With Metastatic Renal Cell Carcinoma (mRCC) Treated With Antiangiogenic Therapies.

Clin Genitourin Cancer 2018 10 21;16(5):369-375.e1. Epub 2018 May 21.

U1086 INSERM-UCBN "Cancers & Préventions", Normandie Université, Caen, France; Departments of Clinical Research Unit, Centre François Baclesse, Caen, France; Department of Medical Oncology, Centre François Baclesse, Caen, France. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clgc.2018.05.013DOI Listing
October 2018

Immune Checkpoint Inhibitors: Toward New Paradigms in Renal Cell Carcinoma.

Drugs 2018 Sep;78(14):1443-1457

Department of Medical Oncology, Gustave Roussy, 114 rue Edouard Vaillant, 94800, Villejuif, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s40265-018-0970-yDOI Listing
September 2018

Sunitinib Alone or after Nephrectomy in Metastatic Renal-Cell Carcinoma.

N Engl J Med 2018 Aug 3;379(5):417-427. Epub 2018 Jun 3.

From the Departments of Urology (A.M., M.-O.T.) and Medical Oncology (S.O.), Hôpital Européen Georges-Pompidou, Assistance Publique-Hôpitaux de Paris (AP-HP), Université Paris-Descartes, and Paris Descartes Necker-Cochin Clinical Research Unit, AP-HP (S.C.), Paris, the Department of Medical Oncology, Bordeaux University Hospital (A.R.), the Department of Medical Oncology, Hôpital Saint André, Centre Hospitalier Universitaire (CHU) de Bordeaux (M.G.-G.), and the Department of Urology, CHU de Bordeaux and Université de Bordeaux (J.-C.B.), Bordeaux, Biometrics Unit, Cancer Institute of Montpellier, University of Montpellier, Montpellier (S.T.), the Department of Urology, CHU Rangueil (J.-B.B.), and the Department of Medical Oncology, Institut Universitaire du Cancer Toulouse-Oncopole (C.C.), Toulouse, the Department of Urology, University of Rennes (K.B.), and the Department of Medical Oncology, Centre Eugene Marquis (B.L.), Rennes, the Department of Medical Oncology, Institut de Cancerologie de Lorraine, Vandoeuvre lès Nancy (L. Geoffrois), the Department of Medical Oncology, CHU Besançon, Oncologie, and Université de Franche-Comte, INSERM Unité Mixte de Recherche (UMR) 1098, Structure Fédérative de Recherche Ingénierie et Biologie Cellulaire et Tissulaire, Besançon (A.T.-V.), the Department of Urology, CHU François Mitterrand, Dijon (L.C.), the Department of Urology, CHU Strasbourg, Translational Medicine Federation Strasbourg, Strasbourg (H.L.), the Department of Urology, Gabriel Montpied Hospital, and Clermont Auvergne University, Clermont-Ferrand (L. Guy), the Department of Medical Oncology, Centre de Recherche en Cancerologie de Marseille, INSERM UMR 1068, Centre National de la Recherche Scientifique UMR 7258 and Institut Paoli-Calmettes (G.G.), and the Department of Urology, Hôpital la Conception (E.L.), Aix Marseille Université, Marseille, the Department of Medical Oncology, Institut de Cancerologie de l'Ouest, Nantes (F.R.), the Department of Medical Oncology, CHU Bretonneau, and the Department of Medicine, Université François Rabelais, Tours (C.L.), the Department of Urology, Mont de Marsan General Hospital, Mont de Marsan (J.-J.P.), the Departments of Medical Oncology (C.T.) and Urology (T.L.), Hôpital Foch, Suresnes, the Department of Urology, Imagerie Adaptative Diagnostique et Interventionnelle INSERM Unité 1254, CHU de Nancy, Brabois (J.H.), the Department of Medical Oncology, Institut Gustave Roussy and Université Paris-Saclay, Villejuif (L.A., B.E.), and Université Versailles, St.-Quentin-en-Yvelines (T.L.) - all in France; the Department of Urology, Haukeland University Hospital (C.B.), and the Department of Clinical Medicine, University of Bergen (C.B.), Bergen, Norway; and the Department of Urology, Royal Free Hospital, London (M.A.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1803675DOI Listing
August 2018

Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma.

N Engl J Med 2018 Apr 21;378(14):1277-1290. Epub 2018 Mar 21.

From Memorial Sloan Kettering Cancer Center, New York (R.J.M.), and Roswell Park Cancer Institute, Buffalo (S.G.) - both in New York; University of Texas M.D. Anderson Cancer Center, Houston (N.M.T., P. Sharma); Beth Israel Deaconess Medical Center, Dana-Farber/Harvard Cancer Center (D.F.M.), and Dana-Farber Cancer Institute, Brigham and Women's Hospital, and Harvard Medical School (T.K.C.), Boston; Centro Internacional de Estudios Clínicos (O.A.F.) and Fundación Arturo López Pérez (P. Salman), Santiago, Chile; Palacký University and University Hospital Olomouc, Olomouc, Czech Republic (B.M.); Fox Chase Cancer Center, Philadelphia (E.R.P.); Hôpitaux Universitaires de Strasbourg, Strasbourg (P.B.), Bordeaux University Hospital, Hôpital Saint-André, Bordeaux (A.R.), and Institut Gustave Roussy, Villejuif (B.E.) - all in France; Istituto di Ricovero e Cura a Carattere Scientifico San Matteo University Hospital Foundation, Pavia (C.P.), and Ospedale San Donato, Azienda Unità Sanitaria Locale Toscana Sud-Est, Istituto Toscano Tumori, Arezzo (S.B.) - both in Italy; Barts Cancer Institute, Cancer Research UK Experimental Cancer Medicine Centre, Queen Mary University of London, Royal Free NHS Trust (T.P.), and Cancer Research UK (R.H.), London; Aarhus University Hospital, Aarhus, Denmark (F.D.); Davidoff Cancer Center, Rabin Medical Center, Petah Tikva, and Tel Aviv University, Tel Aviv - both in Israel (V.N.); British Columbia Cancer Agency, Vancouver, Canada (C.K.K.); Westmead Hospital and Macquarie University, Sydney (H.G.); Jena University Hospital, Jena, Germany (M.-O.G.); Centro de Pesquisa em Oncologia, Hospital São Lucas, Porto Alegre, Brazil (C.H.B.); Niigata University, Niigata, Japan (Y.T.); Hospital Universitario 12 de Octubre, Madrid (D.C.); Cleveland Clinic Taussig Cancer Institute, Cleveland (B.I.R.); Bristol-Myers Squibb, Princeton, NJ (A.C.C., S.M., M.B.M., M.W.-R., J.D.); and Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore (H.J.H.).

View Article

Download full-text PDF

Source
http://www.nejm.org/doi/10.1056/NEJMoa1712126
Publisher Site
http://dx.doi.org/10.1056/NEJMoa1712126DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5972549PMC
April 2018

Cabozantinib, a New Standard of Care for Patients With Advanced Renal Cell Carcinoma and Bone Metastases? Subgroup Analysis of the METEOR Trial.

J Clin Oncol 2018 03 8;36(8):765-772. Epub 2018 Jan 8.

Bernard Escudier, Institut Gustave Roussy, Villejuif; Stephane Oudard, Hôpital Européen Georges Pompidou, Paris; Frederic Rolland, Centre René Gauducheau Centre de Lutte Contre Le Cancer Nantes, Saint-Herblain, France; Thomas Powles, Barts Cancer Institute, Queen Mary University of London, London, United Kingdom; Robert J. Motzer, Memorial Sloan Kettering Cancer Center, New York, NY; Thomas Olencki, Ohio State University, Columbus, OH; Osvaldo Arén Frontera, Centro Internacional de Estudios Clinicos, Santiago, Chile; Piotr Tomczak, Szpital Kliniczny Przemienienia Panskiego Uniwersytetu Medycznego, Poznań, Poland; Daniel Castellano, Hospital Universitario 12 de Octubre, Madrid, Spain; Leonard J Appleman, University of Pittsburgh Medical Center, Pittsburgh, PA; Harry Drabkin, Medical University of South Carolina, Charleston, SC; Daniel Vaena, University of Iowa Hospitals and Clinics, Iowa City, IA; Steven Milwee, Jillian Youkstetter, and Julie C. Lougheed, Exelixis, Inc., San Francisco, CA; Sergio Bracarda, Ospedale San Donato, Istituto Toscano Tumori (ITT), Arezzo, Italy; and Toni K. Choueiri, Dana-Farber Cancer Institute, Boston, MA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2017.74.7352DOI Listing
March 2018

Quality of Life Outcomes for Cabozantinib Versus Everolimus in Patients With Metastatic Renal Cell Carcinoma: METEOR Phase III Randomized Trial.

J Clin Oncol 2018 03 29;36(8):757-764. Epub 2018 Jan 29.

David Cella, Northwestern University Feinberg School of Medicine, Chicago, IL; Bernard Escudier, Institut Gustave Roussy, Villejuif; Florence Marteau, Ipsen Pharma, Boulogne-Billancourt; Paul Williams, Mapi Group, Lyon, France; Nizar M. Tannir, University of Texas MD Anderson Cancer Center Hospital, Houston; Hans J. Hammers, University of Texas Southwestern Medical Center; Thomas E. Hutson, Texas Oncology-Baylor Sammons Cancer Center, Dallas, TX; Thomas Powles, Queen Mary University of London, London, United Kingdom; Frede Donskov, Aarhus University Hospital, Aarhus, Denmark; Katriina Peltola, Helsinki University Hospital Cancer Center, Helsinki, Finland; Manuela Schmidinger, Medical University of Vienna, Vienna, Austria; Daniel Y.C. Heng, University of Calgary, Calgary, Alberta, Canada; Paul N. Mainwaring, Icon Cancer Care, Brisbane, Queensland, Australia; Jae Lyun Lee, University of Ulsan College of Medicine, Seoul, South Korea; Bruce J. Roth, Washington University in St Louis, St Louis, MO; John Baer, Milan Mangeshkar, and Christian Scheffold, Exelixis, South San Francisco; Sumanta Pal, City of Hope National Medical Center, Duarte, CA; Robert J. Motzer, Memorial Sloan Kettering Cancer Center, New York, NY; and Toni K. Choueiri, Dana-Farber Cancer Institute, Boston, MA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2017.75.2170DOI Listing
March 2018

New Insights into Adjuvant Renal Cell Carcinoma Treatment with Vascular Endothelial Growth Factor Inhibitors: What Have We Learned So Far?

Eur Urol 2018 01 8;73(1):1-3. Epub 2017 Sep 8.

Department of Urology, University of Munich, Klinikum Grosshadern, Munich, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.eururo.2017.08.020DOI Listing
January 2018

Everolimus Versus Axitinib as Second-line Therapy in Metastatic Renal Cell Carcinoma: Experience From Institut Gustave Roussy.

Clin Genitourin Cancer 2017 12 12;15(6):e1081-e1088. Epub 2017 Aug 12.

Department of Medical Oncology, Gustave Roussy, Villejuif, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clgc.2017.07.015DOI Listing
December 2017

Pediatric Patient With Renal Cell Carcinoma Treated by Successive Antiangiogenics Drugs: A Case Report and Review of the Literature.

J Pediatr Hematol Oncol 2017 07;39(5):e279-e284

Departments of *Pediatric Oncology, Adolescents and Young Adults †Translational Research ‡Radiology §Pathology ¶Somatic Genetics ††INSERM U830 Research Center, Institut Curie ∥Department of Pediatric Surgery, Necker Enfants-Malades Hospital, Assistance Publique #Department of Pediatrics, University of Paris-Descartes, Sorbonne Paris Cité, Paris **Department of Cancer Medicine, Gustave Roussy, Cancer Campus, Grand Paris, University of Paris-Sud, Villejuif, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/MPH.0000000000000774DOI Listing
July 2017

Antiangiogenic therapy combined with immune checkpoint blockade in renal cancer.

Angiogenesis 2017 May 11;20(2):205-215. Epub 2017 Apr 11.

Department of Urology, The Netherlands Cancer Institute, Postbus 90203, 1006 BE, Amsterdam, The Netherlands.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10456-017-9550-0DOI Listing
May 2017

Nivolumab in renal cell carcinoma: latest evidence and clinical potential.

Ther Adv Med Oncol 2017 Mar 11;9(3):171-181. Epub 2016 Dec 11.

Département de médecine Oncologique, Gustave Roussy, Université Paris-Saclay, Villejuif, F-94805, 114 Rue Edouard Vaillant, 94800 Villejuif, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1758834016679942DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5349425PMC
March 2017

Sunitinib: Ten Years of Successful Clinical Use and Study in Advanced Renal Cell Carcinoma.

Oncologist 2017 01 2;22(1):41-52. Epub 2016 Nov 2.

Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, California, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1634/theoncologist.2016-0197DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5313263PMC
January 2017

Assessment of Early Tumour Shrinkage: Ready for Integration in the Treatment Strategy for Metastatic Renal Cell Carcinoma?

Eur Urol 2016 12 5;70(6):1016-1018. Epub 2016 Aug 5.

Genitourinary Oncology, Department of Medicine, Gustave Roussy Université Paris-Saclay, Villejuif, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.eururo.2016.07.050DOI Listing
December 2016

Adjuvant Sunitinib in High-Risk Renal-Cell Carcinoma after Nephrectomy.

N Engl J Med 2016 12 9;375(23):2246-2254. Epub 2016 Oct 9.

From the Department of Medical Oncology, Bordeaux University Hospital, Bordeaux (A.R.), Department of Medical Oncology, Institut Gustave Roussy, Villejuif (B.E.), Medical Oncology, Centre Eugene Marquis, Rennes (B.L.), and Department of Urology, Bicêtre Hospital, Paris-Saclay University, Le Kremlin Bicêtre (J.-J.P.) - all in France; Department of Medicine, Memorial Sloan Kettering Cancer Center (R.J.M.), and Pfizer (K.R.) - both in New York; Department of Clinical and Experimental Medicine, University of Surrey, Surrey, United Kingdom (H.S.P.); Division of Medical Oncology, Duke Cancer Institute, Durham, NC (D.J.G.); Department of Urology, Ronald Reagan UCLA Medical Center, Los Angeles (A.J.P.), and Pfizer, La Jolla (X.L., J.-F.M.) - both in California; Spire Roding Hospital, London (A.P.); Department of Urology, Taipei Veterans General Hospital, Taipei, Taiwan (Y.-H.C.); Department of Oncology, Aarhus University Hospital, Aarhus, Denmark (F.D.); Department of Urology, Charité Universitätsmedizin Berlin, Berlin (A.M.), and Department of Urology, University Hospital of Munich, Munich (M.S.) - both in Germany; Divisions of Oncology and Urology, Azienda Ospedaliera di Rilievo Nazionale A. Cardarelli, Naples, Italy (G.C.); Klinika Onkologii Oddzial Chemioterapii, Poznan, Poland (P.T.); Department of Urology, Slovak Medical University, Bratislava, Slovakia (J.B.); and Pfizer, Milan (P.G., M.L.), and Collegeville, PA (M.C.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1611406DOI Listing
December 2016

Predicting and preventing thromboembolic events in patients receiving cisplatin-based chemotherapy for germ cell tumours.

Eur J Cancer 2016 12 4;69:151-157. Epub 2016 Nov 4.

Department of Cancer Medicine, Institut Gustave Roussy, Université Paris-Sud, 94800 Villejuif, France. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejca.2016.10.003DOI Listing
December 2016

Cabozantinib for the treatment of renal cell carcinoma.

Expert Opin Pharmacother 2016 Dec 22;17(18):2499-2504. Epub 2016 Nov 22.

a Department of Medical Oncology , Gustave Roussy , Villejuif , France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14656566.2016.1258059DOI Listing
December 2016

Immunotherapy for Renal Cancer: Sequencing and Combinations.

Eur Urol Focus 2016 Dec 20;2(6):582-588. Epub 2017 Apr 20.

Department of Medicine, Section of Hematology-Oncology, University of Alabama at Birmingham (UAB), Birmingham, AL, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.euf.2017.04.002DOI Listing
December 2016

Improvement in survival end points of patients with metastatic renal cell carcinoma through sequential targeted therapy.

Cancer Treat Rev 2016 Nov 10;50:109-117. Epub 2016 Sep 10.

Institut Gustave Roussy, Villejuif, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ctrv.2016.09.002DOI Listing
November 2016

Renal Cell Carcinoma Programmed Death-ligand 1, a New Direct Target of Hypoxia-inducible Factor-2 Alpha, is Regulated by von Hippel-Lindau Gene Mutation Status.

Eur Urol 2016 10 23;70(4):623-632. Epub 2015 Dec 23.

INSERM (Institut National de la Santé et de la Recherche Médicale) UMR1186, Laboratory Integrative Tumor Immunology and Genetic Oncology, Villejuif, France; INSERM, Gustave Roussy, Univ. Paris-Sud, Université Paris-Saclay, Villejuif, F-94805, France. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.eururo.2015.11.029DOI Listing
October 2016

Acute neurovascular events in cancer patients receiving anti-vascular endothelial growth factor agents: Clinical experience in Paris University Hospitals.

Eur J Cancer 2016 10 15;66:75-82. Epub 2016 Aug 15.

Department of Neurology, OncoNeuroTox Center, Paris, France; Department of Neurology, Val-de-Grâce Teaching Hospital, Service de Santé des Armées, 74, boulevard de Port Royal, 75005 Paris, France; Department of Neurology, Cognition an Action Group (COGNAC-G) UMR 8257 Centre National de la Recherche Scientifique, Service de Santé des Armées, Paris Descartes University, 45, rue des Saints-Pères, 75006 Paris, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejca.2016.07.008DOI Listing
October 2016

Hypertension and Angiotensin System Inhibitors in Patients with Metastatic Renal Cell Carcinoma.

Oncol Rev 2016 Oct 24;10(2):298. Epub 2016 Nov 24.

Gustave Roussy Cancer Center, University of Paris-Saclay , Villejuif, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4081/oncol.2016.298DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5136757PMC
October 2016

Safety of available treatment options for renal cell carcinoma.

Expert Opin Drug Saf 2016 Aug 23;15(8):1097-106. Epub 2016 May 23.

a Gustave Roussy Cancer Campus.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14740338.2016.1184643DOI Listing
August 2016

Early PSA response is an independent prognostic factor in patients with metastatic castration-resistant prostate cancer treated with next-generation androgen pathway inhibitors.

Eur J Cancer 2016 07 3;61:44-51. Epub 2016 May 3.

Department of Cancer Medicine, Gustave Roussy, Cancer Campus, Grand Paris, University of Paris-Sud, Villejuif, France. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejca.2016.03.070DOI Listing
July 2016

Safety assessment of molecular targeted therapies in association with radiotherapy in metastatic renal cell carcinoma: a real-life report.

Anticancer Drugs 2016 Jun;27(5):427-32

Departments of aRadiotherapy bMedical Oncology, Lucien Neuwirth Cancer Institute, Saint-Priest en Jarez cDepartment of Radiotherapy, General Hospital CH Roanne, Roanne dDepartment of Oncology and Radiotherapy, Val de Grâce Hospital, Paris eDepartment of Medical Oncology, Institut Gustave Roussy, Villejuif fDepartment of Medical Oncology, Léon Bérard Cancer Center, Lyon, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/CAD.0000000000000349DOI Listing
June 2016

Randomized Open-Label Phase II Trial of Apitolisib (GDC-0980), a Novel Inhibitor of the PI3K/Mammalian Target of Rapamycin Pathway, Versus Everolimus in Patients With Metastatic Renal Cell Carcinoma.

J Clin Oncol 2016 05 7;34(14):1660-8. Epub 2016 Mar 7.

Thomas Powles, Queen Mary University of London, London; Christy Ralph, University of Leeds, Leeds; Janet E. Brown, University of Sheffield, Sheffield; Robert E. Hawkins, University of Manchester, Manchester, United Kingdom; Mark R. Lackner, Wei Lin, Bridget O'Keeffe, Yulei Wang, Shan Lu, Jill M. Spoerke, Ling Yuh Huw, Michelle Byrtek, Rui Zhu, and Joseph A. Ware, Genentech, South San Francisco, CA; Robert J. Motzer, Memorial Sloan Kettering Cancer Center, New York, NY; Brian I. Rini, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH; Bernard Escudier, Institut Gustave Roussy, Villejuif; Alain Ravaud, Hospital Saint Andre, Bordeaux; Stéphane Oudard, University Paris Descartes, Paris, France; Daniel Castellano, University Hospital 12 de Octubre, Madrid, Spain; and Michael D. Staehler, University Hospital Munich-Grosshadern, Marchioninistrasse, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2015.64.8808DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5569691PMC
May 2016

Nonfamilial Chronic Serum Alpha-Fetoprotein Increase in a Patient With Clinical Stage I Seminoma.

Clin Genitourin Cancer 2016 Feb 17;14(1):e91-3. Epub 2015 Aug 17.

Department of Cancer Medicine, Institut Gustave Roussy, University of Paris Sud, Villejuif, France. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clgc.2015.07.014DOI Listing
February 2016

Long-Term Safety With Axitinib in Previously Treated Patients With Metastatic Renal Cell Carcinoma.

Clin Genitourin Cancer 2015 Dec 20;13(6):540-7.e1-7. Epub 2015 Jul 20.

Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clgc.2015.07.001DOI Listing
December 2015

Sorafenib-Sunitinib Sequence: The Jury Is Out.

Eur Urol 2015 Nov 14;68(5):848-9. Epub 2015 Jul 14.

Genitourinary Oncology, Gustave Roussy, Villejuif, France. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.eururo.2015.06.050DOI Listing
November 2015

High subcutaneous adipose tissue predicts the prognosis in metastatic castration-resistant prostate cancer patients in post chemotherapy setting.

Eur J Cancer 2015 Nov 13;51(17):2570-7. Epub 2015 Aug 13.

Department of Cancer Medicine, Gustave-Roussy Cancer Campus, Villejuif, University of Paris Sud, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejca.2015.07.042DOI Listing
November 2015

Interleukin-6 as an emerging regulator of renal cell cancer.

Urol Oncol 2015 Nov 18;33(11):476-85. Epub 2015 Aug 18.

Department of Oncology, Military Institute of Medicine, Warsaw, Poland.

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S10781439150035
Publisher Site
http://dx.doi.org/10.1016/j.urolonc.2015.07.010DOI Listing
November 2015

Efficacy of targeted therapies after PD-1/PD-L1 blockade in metastatic renal cell carcinoma.

Eur J Cancer 2015 Nov 4;51(17):2580-6. Epub 2015 Sep 4.

Kidney Cancer Center, Dana-Farber Cancer Institute/Brigham and Women's Hospital, Harvard Medical School, Boston, United States; Kidney Cancer Program, Dana-Farber Harvard Cancer Center, Boston, United States. Electronic address:

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S09598049150080
Publisher Site
http://dx.doi.org/10.1016/j.ejca.2015.08.017DOI Listing
November 2015

Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma.

N Engl J Med 2015 Nov 25;373(19):1803-13. Epub 2015 Sep 25.

From Memorial Sloan Kettering Cancer Center, New York (R.J.M.), and Roswell Park Cancer Institute, Buffalo (S.G.) - both in New York; Institut Gustave Roussy, Villejuif (B.E.), and Bordeaux University Hospital, Hôpital Saint André, Bordeaux (A.R.) - both in France; Beth Israel Deaconess Medical Center (D.F.M.) and Dana-Farber Cancer Institute, Brigham and Women's Hospital, and Harvard Medical School (T.K.C.) - all in Boston; Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore (H.J.H.); Stanford Cancer Institute, Stanford, CA (S.S.); University of Washington and Fred Hutchinson Cancer Research Center, Seattle (S.S.T.); Vanderbilt University Medical Center, Nashville (J.A.S.); Fondazione Istituto Nazionale Tumori, Milan (G.P.); Fox Chase Cancer Center, Philadelphia (E.R.P.); Hospital Universitario 12 De Octubre, Madrid (D.C.); Westmead Hospital and Macquarie University, Sydney (H.G.); Aarhus University Hospital, Aarhus, Denmark (F.D.); Helsinki University Central Hospital and University of Helsinki, Helsinki (P.B.); South West Wales Cancer Institute and Swansea University College of Medicine, Swansea (J.W.), and Royal Marsden Hospital, London (J.L.) - both in the United Kingdom; University Hospital Essen of University of Duisburg-Essen, Germany (T.C.G.); Chiba Cancer Center, Chiba (T.U.), and Niigata University, Niigata (Y.T.) - both in Japan; Hospital Sao Jose, Beneficencia Portuguesa de São Paulo, São Paulo (F.A.S.); British Columbia Cancer Agency, Vancouver, BC, Canada (C.K.); Bristol-Myers Squibb, Lawrenceville (J.S.S., I.M.W.) and Hopewell (L.-A.X.) - both in New Jersey; and M.D. Anderson Cancer Center, University of Texas, Houston (P.S.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1510665DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5719487PMC
November 2015

Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma.

N Engl J Med 2015 Nov 25;373(19):1814-23. Epub 2015 Sep 25.

From the Dana-Farber Cancer Institute, Boston (T.K.C., P.W.K.); Institut Gustave Roussy, Villejuif, France (B.E.); Barts Cancer Institute, Cancer Research UK Experimental Cancer Medicine Centre, Queen Mary University of London, Royal Free NHS Trust, London (T.P.); Icon Cancer Care, South Brisbane, QLD, Australia (P.N.M.); Cleveland Clinic, Cleveland (B.I.R.); Aarhus University Hospital, Aarhus, Denmark (F.D.); Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore (H.H.); Texas Oncology-Charles A. Sammons Cancer Center, Baylor University, Dallas (T.E.H.); University of Ulsan College of Medicine (J.-L.L.) and Seoul National University Hospital (B.K.) - both in Seoul, South Korea; Helsinki University Central Hospital Cancer Center, Helsinki (K.P.); Washington University in St. Louis, St. Louis (B.J.R.); Sunnybrook Odette Cancer Centre, Toronto (G.A.B.), and Tom Baker Cancer Centre, Calgary, AB (D.Y.C.H.) - both in Canada; National Institute of Oncology, Budapest, Hungary (L.G.); Hospital de la Santa Creu i Sant Pau, Barcelona (P.M.); Medical University of Vienna, Vienna (M.S.); Exelixis, South San Francisco, CA (A.B-H., C.H., C.S., G.M.S.); University of Texas M.D. Anderson Cancer Center, Houston (N.M.T.); and the Memorial Sloan Kettering Cancer Center, New York (R.J.M.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1510016DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5024539PMC
November 2015

Current and future strategies in nonclear-cell metastatic renal cell carcinoma.

Curr Opin Urol 2015 Sep;25(5):367-73

Genitourinary Oncology, Gustave Roussy, Villejuif, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/MOU.0000000000000197DOI Listing
September 2015

Prior long response to androgen deprivation predicts response to next-generation androgen receptor axis targeted drugs in castration resistant prostate cancer.

Eur J Cancer 2015 Sep 21;51(14):1946-52. Epub 2015 Jul 21.

Department of Cancer Medicine, Gustave Roussy Institute, Cancer Campus, Grand Paris, University of Paris-Sud, Villejuif, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejca.2015.06.128DOI Listing
September 2015

Algorithms in the First-Line Treatment of Metastatic Clear Cell Renal Cell Carcinoma--Analysis Using Diagnostic Nodes.

Oncologist 2015 Sep 3;20(9):1028-35. Epub 2015 Aug 3.

Division of Haematology and Oncology, Kantonsspital St. Gallen, St. Gallen, Switzerland; Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA; Department of Medical Oncology, San Camillo and Forlanini Hospitals, Rome, Italy; Department of Oncology, Cambridge University Hospitals National Health Service Foundation, Cambridge, United Kingdom; Gustave Roussy, Villejuif, France; Hämatologie, Hämostaseologie, Onkologie und Stammzelltransplantation, Medizinische Hochschule Hannover, Hannover, Germany; The Royal Marsden Hospital, London, United Kingdom; Department of Oncology, Akershus University Hospital and Medical Faculty of University of Oslo, Oslo, Norway; Policlinico San Matteo Pavia Fondazione IRCCS, Pavia, Italy; Department of Solid Tumor Oncology, Cleveland Clinic, Cleveland, Ohio, USA; Abteilung für Onkologie, Allgemeines Krankenhaus-Universitätskliniken, Wien, Austria; Faculty of Medicine, University of Oslo, Oslo, Norway; Department of Radiation Oncology, Kantonsspital St. Gallen, St. Gallen, Switzerland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1634/theoncologist.2015-0145DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4571803PMC
September 2015

Relapse models for clear cell renal carcinoma - Authors' reply.

Lancet Oncol 2015 Aug;16(8):e378

Institut Gustave Roussy, Villejuif, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S1470-2045(15)00133-3DOI Listing
August 2015